Research article

Clinical features of culture-proven *Mycoplasma pneumoniae* infections at King Abdulaziz University Hospital, Jeddah, Saudi Arabia

Tariq A Madani* and Aisha A Al-Ghamdi

Address: King Abdulaziz University Hospital, Jeddah, Saudi Arabia

E-mail: Tariq A Madani* - tmadani@health.net.sa; Aisha A Al-Ghamdi - aalghamdius@yahoo.com

*Corresponding author

Abstract

Objective: This retrospective chart review describes the epidemiology and clinical features of 40 patients with culture-proven *Mycoplasma pneumoniae* infections at King Abdulaziz University Hospital, Jeddah, Saudi Arabia.

Methods: Patients with positive *M. pneumoniae* cultures from respiratory specimens from January 1997 through December 1998 were identified through the Microbiology records. Charts of patients were reviewed.

Results: 40 patients were identified, 33 (82.5%) of whom required admission. Most infections (92.5%) were community-acquired. The infection affected all age groups but was most common in infants (32.5%) and pre-school children (22.5%). It occurred year-round but was most common in the fall (35%) and spring (30%). More than three-quarters of patients (77.5%) had comorbidities. Twenty-four isolates (60%) were associated with pneumonia, 14 (35%) with upper respiratory tract infections, and 2 (5%) with bronchiolitis. Cough (82.5%), fever (75%), and malaise (58.8%) were the most common symptoms, and crepitations (60%), and wheezes (40%) were the most common signs. Most patients with pneumonia had crepitations (79.2%) but only 25% had bronchial breathing. Immunocompromised patients were more likely than non-immunocompromised patients to present with pneumonia (8/9 versus 16/31, P = 0.05). Of the 24 patients with pneumonia, 14 (58.3%) had uneventful recovery, 4 (16.7%) recovered following some complications, 3 (12.5%) died because of *M pneumoniae* infection, and 3 (12.5%) died due to underlying comorbidities. The 3 patients who died of *M pneumoniae* pneumonia had other comorbidities.

Conclusion: our results were similar to published data except for the finding that infections were more common in infants and preschool children and that the mortality rate of pneumonia in patients with comorbidities was high.

Introduction

*Mycoplasma pneumoniae* is a common cause of upper and lower respiratory tract infections. It remains one of the most frequent causes of atypical pneumonia particularly among young adults.[1,2,3,4,5] Although it is highly transmissible, most infections caused by this organism are relatively minor and include pharyngitis, tracheobronchitis, bronchiolitis, and croup with one fifth of in-
Infections being asymptomatic.[6,7] Only 3-10% of infected subjects develop symptoms consistent with bronchopneumonia and mortality from infection is rare.[6,7] The organism is fastidious and difficult to grow on cultures. Therefore, diagnosis of infections caused by this organism is usually confirmed with serological tests or polymerase chain reaction-gene amplification techniques. At King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia, the facility to perform Mycoplasma culture has been available since January 1997. As published information concerning M. pneumoniae infections in Saudi Arabia is scarce,[8,9,10] we wished to study the epidemiology and clinical features of culture-proven infections caused by this organism at this hospital.

Methods

Institution and patient population

KAUH is a tertiary care teaching hospital with a bed capacity of 265 beds and annual admissions of 18000 to 19000 patients. Patients with M. pneumoniae positive cultures from respiratory specimens were identified over a 24-months period from January, 1997 through December, 1998 for this review.

Data collection

During the study period, respiratory specimens (sputum, nasopharyngeal aspiration, endotracheal secretion, and bronchoalveolar lavage) for M. pneumoniae culture were obtained from patients with upper or lower respiratory tract infections seen as inpatients or in the outpatient or emergency departments. Respiratory specimens were also Gram-stained and cultured for bacteria and viruses. M. pneumoniae serological tests for IgG or IgM were not available at KAUH during the study period. All positive culture results were obtained from the Microbiology laboratory records. Charts of patients were reviewed with standardized data collection. Information collected included patients' demographics, comorbidities, clinical manifestations, complications, and outcome.

Microbiological methods

M. pneumoniae was cultured using the classic M. pneumoniae agar medium (M.P. agar) and the Pneumofast tray (Pneumofast®, International Microbio, Signes, France). Specimens were processed according to the instructions of the manufacturer. The M.P. agars and Pneumofast trays were incubated anaerobically at 37°C and inspected daily for 4 weeks. The organism was identified based on typical colonial morphology (granular colonies, rarely fried-egg-like, 10-150 mm in diameter) on the M.P. agar medium and the change in the Pneumofast broth color from red to orange then to yellow (glucose fermentation) in the absence of turbidity of the broth. Antibiotic sensitivity profile on the Pneumofast tray was also used for identification according to the instructions of the manufacturer. Bacterial and viral cultures were performed using standard methods.

Definitions

M. pneumoniae isolates were considered community-acquired if they were recovered from unhospitalized patients or within 72 hours of admission to the hospital, and nosocomial if they were recovered beyond that period.

Pneumonia was diagnosed based on clinical symptoms and signs, along with radiographic evidence of pneumonia when possible. Severe pneumonia was defined as pneumonia associated with tachycardia (>140/minute), tachypnoea (>30/minute), hypotension (Systolic blood pressure <90 mmHg), hypoxemia (arterial oxygen partial pressure <8 kPa or oxygen saturation <90%), and/or more than 2 areas of consolidation.

Outcome of patients with M. pneumoniae infection was classified into 4 categories; uneventful recovery, recovery following complications, death due to M. pneumoniae infection, or death unrelated to M. pneumoniae infection.

Data Analysis

The Statistical Package for Social Sciences (SPSS) program was used for data analysis. Comparison of categorical data was by Chi-square statistic or Fisher’s exact test for small expected values.

Results

A total of 40 respiratory specimens from 40 patients were positive for M. pneumoniae over the 24-months study period. The demographic and epidemiological characteristics of the patients are summarized in Table 1. Of all isolates, 37 (92.5%) were community-acquired and 3 (7.5%) were nosocomial. Thirty-three (82.5%) patients required admission to the hospital and the remaining 7 (17.5%) were treated as outpatients. Twenty-four isolates (60%) were associated with pneumonia, 14 (35%) with upper respiratory tract infections, and 2 (5%) with bronchiolitis. Of the 24 cases of pneumonia, 21 were confirmed radiologically and the remaining 3 were diagnosed clinically. The two cases of bronchiolitis occurred in 2 children, one and three years old. Thirty-one patients (77.5%) had comorbidities. Eleven patients (27.5%) had cardiopulmonary comorbidities (asthma, 8, lung fibrosis, 1, congestive heart failure, 1, congenital heart disease, 1), 9 patients (22.5%) were immunocompromised (malignancy, 7, steroid therapy, 3, Human immunodeficiency virus infection, 1), and 11 patients (27.5%) had other comorbidities (premature newborns, 2, and one each of myelodysplastic syndrome, myeloproliferative disorders, and syphilis).
liferative disorder, sickle cell anemia, Evan's syndrome, Down syndrome, sarcoidosis, demyelinating disease, cerebral palsy, and spinal muscle atrophy). Organisms concomitantly isolated with *M. pneumoniae* from the respiratory tract included herpes simplex virus type 1 (2 occasions), adenovirus (2 occasions), cytomegalovirus (1 occasion), respiratory syncytial virus (1 occasion), and bacterial isolates (2 occasions: *Acinetobacter* species, 1, and *Enterobacter cloacae*, 1).

Clinical manifestations associated with *M. pneumoniae* infections are summarized in Table 2. Pneumonia was more common than upper respiratory tract infections (57.5 % versus 27.5%, respectively). Immunocompromised patients were more likely to present with pneumonia as opposed to upper respiratory tract infection or bronchiolitis than non-immunocompromised patients (8/9 versus 16/31, *P* = 0.05). Similarly, there was a tendency for patients 60 years of age or older to present with pneumonia more frequently than those below 60 (4/4 versus 20/36, *P* = 0.1). Of the 24 patients with clinically or radiologically confirmed pneumonia, 19 (79.2%) had crepitations and only 6 (25%) had bronchial breath sounds on physical examination. Of the 16 patients in whom wheezes were detected, 9 (56.3%) were not known to have asthma or other obstructive airway disease.

| Table 1: Epidemiological characteristics of 40 patients with *M. pneumoniae* infections. |
| Variable | Frequency (%) |
|----------|---------------|
| Age Groups: | |
| 0-1 year | 13 (32.5) |
| 1.1-5 year | 9 (22.5) |
| 5.1-15 year | 5 (12.5) |
| 15.1-30 year | 1 (2.5) |
| 30.1 -50 year | 5 (12.5) |
| 50.1 -70 year | 5 (12.5) |
| >70 year | 2 (5.0) |
| Gender: | |
| Male | 24 (60) |
| Female | 16 (40) |
| Nationality: | |
| Saudi | 23 (57.5) |
| Non-Saudi | 17 (42.5) |
| Season: | |
| Summer | 4(10) |
| Fall | 14 (35) |
| Winter | 10 (25) |
| Spring | 12 (30) |
| Community-acquired / Hospital-acquired | 37 (92.5) / 3 (7.5) |
| Patients with comorbidities | 31 (77.5) |

| Table 2: Clinical manifestations of culture-proven *M. pneumoniae* infections in 40 patients. |
| Variable | Frequency (%) |
|----------|---------------|
| Type of infection: | |
| Pneumonia | 24 (60) |
| Upper respiratory tract infection | 14 (35) |
| Bronchiolitis | 2(5) |
| Fever: | |
| Low grade (37.2-38°C) | 16 (40) |
| Moderate grade (38.1-39°C) | 12 (30) |
| High grade (>39°C) | 2(5) |
| Chills | 3 (7.5) |
| Malaise | 20/34 (58.8) |
| Pleuritic chest pain | 3 (7.5) |
| Cough: | |
| Absent | 11(27.5) |
| Mild | 18(45) |
| Moderate | 8(20) |
| Severe | 3 (7.5) |
| Sputum production | |
| No sputum (dry cough) | 11(37.9) |
| Mild | 12(41.4) |
| Moderate | 2 (6.9) |
| Copious | 0 |
| Unknown (babies) | 4(13.8) |
| Color of sputum: | |
| White | 11(78.6) |
| Yellow | 3 (21.4) |
| Bronchial breathing | 6(25) |
| Crepitations | 24 (60) |
| Wheezes | 16 (40) |
| Pleural effusion | 3 (7.5) |
| Abnormal chest x-ray | 21 (52.5) |
| Pattern of chest x-ray abnormalities: | |
| Localized infiltrate(s): | |
| 1 area | 5 (23.8) |
| 2 areas | 4 (19) |
| 3 or more areas | 2 (9.5) |
| Bronchopneumonia | 5 (23.8) |
| Bronchiolitis | 1 (4.8) |
| Interstitial infiltrate | 2 (9.5) |
| ARDS | 3 (14.3) |

1 For 29 patients with cough. 2 For 14 patients with productive cough. 3 For 24 patients with pneumonia. 4 For 21 patients with radiologically-confirmed pneumonia. 5 ARDS=Acute respiratory distress syndrome.
Complications and outcome of patients are shown in Table 3. Of the 24 patients with pneumonia, 21 (87.5%) were admitted to the hospital, and 20 (83.3%) had co-morbidities. All patients with upper respiratory tract infections (11 patients) or bronchiolitis (2 patients) had uneventful recovery. Of the 24 patients with pneumonia, 14 (58.3%) had uneventful recovery, 4 (16.7%) recovered following some complications (acute respiratory distress syndrome, 2, respiratory failure, 1, septic shock, 1), 3 (12.5%) died because of M pneumoniae infection, and 3 (12.5%) died due to underlying comorbidities. The 3 patients who died of M pneumoniae pneumonia had other comorbidities; one had congestive heart failure, the second had congenital heart disease, and the third was a 3-months old infant born prematurely at 32 weeks of gestation who previously had 3 episodes of pneumonia due to other pathogens.

Discussion

Mycoplasma pneumoniae is one of the most common causes of atypical pneumonia accounting for 5-23% of community-acquired pneumonia.[1,2,3,4,5] In a study of 511 children with acute respiratory tract infection in Riyadh, Saudi Arabia, Mycoplasma pneumoniae was found to be the second most common causative agent after Respiratory syncytial virus (RSV) accounting for 9% of all cases.[8] In a study of 112 adult patients with community acquired pneumonia admitted to a military hospital in Riyadh, Saudi Arabia, this organism accounted for 6% of all cases.[9] In another retrospective study of 567 pneumonia episodes in adult patients from Al-Qassim area, the organism accounted for 23% of all episodes.[10] The organism also causes other relatively minor infections such as pharyngitis, tracheobronchitis, bronchiolitis, and croup. It is transmitted from person-to-person by infected respiratory droplets during close contact. It is most common in school-aged children, military recruits, and college students.[11] Most cases occur singly or as family outbreaks. Larger outbreaks can also occur in closed populations such as military recruit camps or boarding schools.[12] Infection occurs most frequently during the fall and winter in temperate climates but may develop year-round.[13] The average incubation period is 3 weeks following exposure.[6] Although rare, complications are protean and may involve virtually any organ system such as the respiratory system (e.g.: pleurisy, pneumothorax, acute respiratory distress syndrome, lung abscess), the hematologic system (e.g.: hemolytic anemia, intravascular coagulation, thrombocytopenia), the dermatologic system (e.g.: maculopapular or urticarial rashes, erythema multiforme, erythema nodosum), the musculoskeletal system (e.g.: myalgias, arthralgias, arthritis), the cardiovascular system (e.g.: pericarditis, myocarditis), the nervous system (e.g.: meningoen-cephalitis, Guillain-Barre syndrome, neuropathies, acute psychosis), or the eye (optic disc edema, optic nerve atrophy, retinal exudation and hemorrhages).[6,7,14,15,16,17,18] Immunity following infection is not long lasting.[11]

In our study, the infection affected all age groups but was most common in infants (32.5%) and preschool children (22.5%), and least common in adults aged 15 to 30 years (2.5%) and elderly above 70 years of age (5%). This contrasts with data from temperate countries where the infection is most common in school-aged children, and young adults.[11] One possible explanation for this difference is that infants and preschool children perhaps had more severe infections than did school-aged children, and young adults which prompted presentation of the former group to the hospital. The infection occurred year-round, but was most common in the fall (35%), and spring (30%), and least common in the summer (10%). Most infections were community-acquired (92.5%).

More than one half of patients (57.5%) presented with pneumonia, and about a third (27.5%) presented with upper respiratory tract infection, immunocompromised patients and patients 60 years of age or older were more likely to present with pneumonia as opposed to upper respiratory tract infection than non-immunocompromised patients or those below 60 years of age. Cough (82.5%), fever (75%), and malaise (58.8%) were the most common presenting symptoms. Cough was usually dry or slightly productive of white sputum and mild to moderate in severity. Most febrile patients had mild to mod-
erate fever of 39°C or less; high-grade fever of more than 39°C was rare. Crepitations (60%), and wheezes (40%) were the most common signs. Wheezes were as common in patients with no history of obstructive airway disease (9 patients) as it was in those with such a history (7 patients). Bronchial breathing as a sign of consolidation was detected in only one fourth of patients with pneumonia, which is consistent with the known disparity between clinical and radiological signs of *M. pneumoniae* pneumonia. Crepitations, however, were detected in the majority (79.2%) of patients. Pleuritic chest pain and pleural effusion were rare.

More than half (56.5%) of the patients with pneumonia had uneventful recovery. Mortality from *M. pneumoniae* pneumonia was high (12.5%) and occurred only in patients with underlying comorbidities. None of the 9 patients with no underlying comorbidities died of *M. pneumoniae* pneumonia. The relatively high complications rate (16.7%) and mortality (12.5%) related to *M. pneumoniae* pneumonia are likely due to selection bias as most patients with pneumonia were sick enough to require admission to the hospital (21/24 or 87.5%) and most of them had comorbidities (20/24 or 83.3%).

In conclusion, our data shed some light on the epidemiology and clinical features of *M. pneumoniae* infections in one of the Saudi tertiary care centers. The data are comparable to those of other countries except for the finding that infections were more common in infants and preschool children than in school children and young adults. Additionally, mortality attributable to *M. pneumoniae* pneumonia was relatively high in patients with comorbidities. It is hoped this information will assist clinicians in their approach and management of respiratory tract infections.

Acknowledgments
We wish to thank Mrs. Fatin S. Gazzaz, Microbiologist, and Mr. Yusri A. Al-Surujii, Microbiology technologist, King Abdulaziz University Hospital, for performing *Mycoplasma pneumoniae* cultures and for providing the list of patients for this study.

References
1. Bartlett JG, Mundy LM. Community-acquired pneumonia. *N Engl J Med* 1995, 333:1618-1624
2. Marrie TJ, Peeling RW, Fine MJ, et al: Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course. *Am J Med* 1996, 101:508-515
3. Lieberman D, Schlaeffer F, Lieberman D, et al: *Mycoplasma pneumoniae* community-acquired pneumonia: A review of 101 hospitalized adult patients. *Respiration* 1996, 63:261-266
4. Maarten G, Lewis SJ, de Goveia C, et al: “Atypical” bacteria are a common cause of community-acquired pneumonia in hospitalized adults. *S Afr Med J* 1994, 84:678-682
5. Marrie TJ. *Mycoplasma pneumoniae* pneumonia requiring hospitalization, with emphasis on infection in the elderly. *Arch Intern Med* 1993, 153:488-494
6. Clyde WA Jr: Clinical overview of typical *Mycoplasma pneumoniae* infections. *Clin Infect Dis* 1993, 17(Suppl I):532-536
7. Foy HM: Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. *Clin Infect Dis* 1993, 17(Suppl I):537-546
8. Al Rashed A: Role of Mycoplasma pneumoniae in acute respiratory-tract infections in Saudi paediatric patients. *Ann Trop Med Parasitol* 1998, 92(5):595-601
9. Mohamed AR, Evans DA: The spectrum of pneumonia in 1983 at the Riyadh Armed Forces Hospital. *J Infect* 1987, 14(1):31-37
10. Kurashi NY, Al-Hamdan A, Ibrahim EM, Al-Irdissi HY, Al-Bayani TH: Community acquired acute bacterial and atypical pneumonia in Saudi Arabia. *Thorax* 1992, 47(2):115-118
11. Foy HM, Kenny G, Cooney M, et al: Long-term epidemiology of infections with *Mycoplasma pneumoniae*. *J Infect Dis* 1979, 139:681-687
12. Mogabgab WJ: *Mycoplasma pneumoniae* and adenovirus respiratory illness in military and university personnel, 1959-1966. *Am Rev Respir Dis.* 1968, 97:345-358
13. Luby JP: *Pneumonia caused by Mycoplasma pneumoniae infection*. *Clin Chest Med* 1991, 12:237-244
14. Ali NJ, Sillis M, Andrews B, Jenkins P, Harrison B: The clinical spectrum and diagnosis of *Mycoplasma pneumoniae* infection. *Q J Med* 1986, 227:241-251
15. Cherry JD: Anemia and Mucocutaneous lesions due to *Mycoplasma pneumoniae* infections. *Clin Infect Dis* 1993, 17(Suppl I):S47-S51
16. Sands MJ Jr, Satz JE, Turner WE, Soloff LA: Pericarditis and perimyocarditis associated with active *Mycoplasma pneumoniae* infection. *Ann Intern Med* 1977, 86:544-548
17. Kenney RT, Li JS, Clyde WA Jr, et al: *Mycoplasma pericarditis: evidence of invasive disease*. *Clin Infect Dis* 1993, 17(Suppl I):S58-S62
18. Koskineni M: CNS manifestations associated with *Mycoplasma pneumoniae* infections. *Summary of cases at the University of Helsinki and review*. *Clin Infect Dis* 1993, 17(Suppl I):S52-S57

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/content/backmatter/1471-2334-1-6-b1.pdf

Publish with BioMedcentral and every scientist can read your work free of charge

"BioMedcentral will be the most significant development for disseminating the results of biomedical research in our lifetime."

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with BMC and your research papers will be:
- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/submissions/
editorial@biomedcentral.com